Identification

Name
Protriptyline
Accession Number
DB00344  (APRD00441)
Type
Small Molecule
Groups
Approved
Description

Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Protriptyline may be used for the treatment of depression.

Structure
Thumb
Synonyms
  • 3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine
  • 3-(5H-Dibenzo[a,D]cyclohepten-5-yl)-N-methyl-1-propanamine
  • 5-(3-Methylaminopropyl)-5H-dibenzo[a,D]cycloheptene
  • 7-(3-Methylaminopropyl)-1,2:5,6-dibenzocycloheptatriene
  • Amimetilina
  • N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propanamine
  • N-Methyl-5H-dibenzo[a,D]cycloheptene-5-propylamine
  • Protriptilina
  • Protriptylin
  • Protriptyline
  • Protriptylinum
External IDs
MK 240 / MK-240
Product Ingredients
IngredientUNIICASInChI Key
Protriptyline hydrochloride44665V00O81225-55-4OGQDIIKRQRZXJH-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Triptil Tab 10mgTablet10 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1966-12-312001-01-25Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Protriptyline HydrochlorideTablet, film coated5 mg/1OralEpic Pharma, LLC2013-01-09Not applicableUs
Protriptyline hydrochlorideTablet, film coated10 mg/1OralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
Protriptyline HydrochlorideTablet5 mg/1OralWest Ward Pharmaceutical2008-09-16Not applicableUs
Protriptyline HydrochlorideTablet, film coated10 mg/1OralEpic Pharma, LLC2013-01-09Not applicableUs
Protriptyline HydrochlorideTablet, film coated5 mg/1OralRising Pharmaceuticals2010-06-11Not applicableUs
Protriptyline HydrochlorideTablet10 mg/1OralWest Ward Pharmaceutical2008-09-16Not applicableUs
Protriptyline hydrochlorideTablet, film coated5 mg/1OralHi Tech Pharmacal Co., Inc.2013-10-28Not applicableUs
Protriptyline HydrochlorideTablet, film coated10 mg/1OralRising Pharmaceuticals2010-06-11Not applicableUs
International/Other Brands
Triptil / Vivactil (Odyssey)
Categories
UNII
4NDU154T12
CAS number
438-60-8
Weight
Average: 263.3767
Monoisotopic: 263.167399677
Chemical Formula
C19H21N
InChI Key
BWPIARFWQZKAIA-UHFFFAOYSA-N
InChI
InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3
IUPAC Name
methyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)amine
SMILES
CNCCCC1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Pharmacodynamics

Protriptyline is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the reuptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for approximately two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: α1 and β1 receptors are sensitized, α2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of action

Protriptyline acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
ASodium-dependent serotonin transporter
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Cumulative urinary excretion during 16 days accounted for approximately 50% of the drug. The fecal route of excretion did not seem to be important.

Half life
Not Available
Clearance
Not Available
Toxicity

Side effects include anxiety, blood disorders, confusion, decreased libido, dizziness, flushing, headache, impotence, insomnia, low blood pressure, nightmares, rapid or irregular heartbeat, rash, seizures, sensitivity to sunlight, stomach and intestinal discomfort, sedation, hypotension, blurred vision, dry mouth, constipation, urinary retention, postural hypotension, tachycardia, hypertension, ECG changes, heart failure, impaired memory and delirium, and precipitation of hypomanic or manic episodes in bipolar depression. Withdrawal symptoms include gastrointestinal disturbances, anxiety, and insomnia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Protriptyline can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineProtriptyline may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Protriptyline can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineProtriptyline may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineProtriptyline may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Protriptyline.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the serotonergic activities of Protriptyline.Experimental
AbirateroneThe serum concentration of Protriptyline can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Protriptyline.Approved
AcenocoumarolProtriptyline may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Protriptyline.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Protriptyline.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Protriptyline.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Acetophenazine.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Protriptyline.Approved, Vet Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Protriptyline.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Protriptyline.Approved
AgmatineProtriptyline may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Protriptyline.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Alaproclate.Experimental
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Protriptyline.Experimental, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Protriptyline.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Protriptyline.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Protriptyline.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Protriptyline.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Almotriptan.Approved, Investigational
AlogliptinThe serum concentration of Protriptyline can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Protriptyline can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Protriptyline.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Protriptyline.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Protriptyline.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Protriptyline.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Protriptyline.Approved, Investigational
AmiodaroneProtriptyline may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Protriptyline.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Protriptyline.Approved
AmobarbitalThe metabolism of Protriptyline can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Protriptyline.Experimental
AmphetamineProtriptyline may increase the stimulatory activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Protriptyline can be increased when it is combined with Amprenavir.Approved
AnagrelideProtriptyline may increase the QTc-prolonging activities of Anagrelide.Approved
Antithrombin III humanThe serum concentration of Protriptyline can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Protriptyline can be increased when it is combined with Apixaban.Approved
ApomorphineProtriptyline may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineProtriptyline may decrease the antihypertensive activities of Apraclonidine.Approved
AprotininThe serum concentration of Protriptyline can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Protriptyline can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Protriptyline.Approved, Investigational
Arsenic trioxideProtriptyline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherProtriptyline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Protriptyline.Approved
AsenapineProtriptyline may increase the QTc-prolonging activities of Asenapine.Approved
AsunaprevirThe serum concentration of Protriptyline can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe serum concentration of Protriptyline can be increased when it is combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Protriptyline.Approved
AtomoxetineThe metabolism of Protriptyline can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Protriptyline.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Protriptyline.Investigational, Vet Approved
AzelastineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinProtriptyline may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Protriptyline.Approved
BambuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Protriptyline can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Protriptyline can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Protriptyline can be increased when it is combined with Batimastat.Experimental
BedaquilineProtriptyline may increase the QTc-prolonging activities of Bedaquiline.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Protriptyline.Approved, Investigational
BenazeprilThe serum concentration of Protriptyline can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinBenmoxin may increase the serotonergic activities of Protriptyline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Protriptyline.Investigational
BenzamidineThe serum concentration of Protriptyline can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Protriptyline.Approved
BenzphetamineProtriptyline may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Protriptyline.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Protriptyline.Approved, Vet Approved
BetaxololThe metabolism of Protriptyline can be decreased when combined with Betaxolol.Approved
BethanidineProtriptyline may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Protriptyline can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Protriptyline can be increased when it is combined with Boceprevir.Approved, Withdrawn
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Protriptyline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Protriptyline.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
BrofaromineBrofaromine may increase the serotonergic activities of Protriptyline.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Protriptyline.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Protriptyline.Experimental
BromocriptineProtriptyline may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Protriptyline.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Protriptyline.Approved, Investigational
BuprenorphineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Protriptyline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Protriptyline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Protriptyline.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Protriptyline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Protriptyline.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Protriptyline.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Protriptyline.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Protriptyline.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Protriptyline.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Protriptyline.Approved
CamostatThe serum concentration of Protriptyline can be increased when it is combined with Camostat.Experimental
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Protriptyline.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Protriptyline.Approved
CandoxatrilThe serum concentration of Protriptyline can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Protriptyline can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Canertinib is combined with Protriptyline.Investigational
CaptoprilThe serum concentration of Protriptyline can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Protriptyline.Illicit, Investigational, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Protriptyline.Approved
CariprazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Carisoprodol.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Protriptyline.Withdrawn
CelecoxibThe metabolism of Protriptyline can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Protriptyline is combined with Celiprolol.Approved, Investigational
CeritinibProtriptyline may increase the QTc-prolonging activities of Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Protriptyline.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Protriptyline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Protriptyline.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Protriptyline.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Protriptyline.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Protriptyline.Approved
ChloroquineProtriptyline may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorphenamine.Approved
ChlorphentermineProtriptyline may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorproethazine.Experimental
ChlorpromazineProtriptyline may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Protriptyline.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Protriptyline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Protriptyline can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Protriptyline can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Protriptyline can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Protriptyline can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Protriptyline can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Protriptyline can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Protriptyline.Approved, Vet Approved
CiprofloxacinProtriptyline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CirazolineProtriptyline may increase the vasopressor activities of Cirazoline.Experimental
CisaprideProtriptyline may increase the arrhythmogenic activities of Cisapride.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Protriptyline.Approved
CitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Citalopram.Approved
ClarithromycinProtriptyline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Protriptyline can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Protriptyline.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Protriptyline.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Protriptyline.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Protriptyline is combined with Clonazepam.Approved, Illicit
ClonidineProtriptyline may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Protriptyline.Experimental
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Protriptyline.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Protriptyline.Approved, Illicit
ClorindioneProtriptyline may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Protriptyline.Experimental
ClotrimazoleThe metabolism of Protriptyline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineProtriptyline may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Protriptyline can be increased when it is combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Protriptyline.Approved
CocaineThe metabolism of Protriptyline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Protriptyline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Protriptyline.Approved
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Protriptyline.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Protriptyline.Approved
CrizotinibProtriptyline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Protriptyline.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Protriptyline.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Protriptyline.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Protriptyline.Approved
DantroleneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Protriptyline.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Protriptyline.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.Investigational
DarexabanThe serum concentration of Protriptyline can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Protriptyline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Protriptyline can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Protriptyline.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Protriptyline.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Protriptyline.Approved, Investigational
DelanzomibThe serum concentration of Protriptyline can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Protriptyline can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Protriptyline can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Protriptyline.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Protriptyline.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Protriptyline.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dexbrompheniramine.Approved
DexmedetomidineProtriptyline may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Protriptyline.Approved
DextroamphetamineProtriptyline may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Protriptyline.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Protriptyline.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Protriptyline.Approved, Investigational
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Protriptyline.Approved, Illicit, Vet Approved
DicoumarolProtriptyline may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Protriptyline.Experimental
DiethylpropionProtriptyline may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Protriptyline.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Protriptyline.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Protriptyline.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Protriptyline.Approved, Illicit
DihydroergotamineProtriptyline may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Protriptyline.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Protriptyline.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Protriptyline.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Protriptyline.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dimenhydrinate.Approved
DiphenadioneProtriptyline may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Protriptyline can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Protriptyline.Approved, Illicit
DipivefrinProtriptyline may decrease the antihypertensive activities of Dipivefrin.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Protriptyline.Approved
DisopyramideProtriptyline may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Protriptyline.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Protriptyline.Approved, Investigational
DofetilideProtriptyline may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronProtriptyline may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneProtriptyline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Protriptyline.Vet Approved
DosulepinThe metabolism of Protriptyline can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Protriptyline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Protriptyline.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Illicit
DronedaroneProtriptyline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Protriptyline.Experimental, Illicit
DroxidopaProtriptyline may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Protriptyline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Protriptyline.Approved
EcabetThe serum concentration of Protriptyline can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Protriptyline.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Protriptyline.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Protriptyline.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Protriptyline can be increased when it is combined with Elafin.Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Protriptyline.Approved
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Protriptyline.Approved, Investigational
EliglustatProtriptyline may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Protriptyline.Investigational
EnalaprilThe serum concentration of Protriptyline can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Protriptyline can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Protriptyline can be increased when it is combined with Enalkiren.Experimental
EnasidenibThe serum concentration of Enasidenib can be increased when it is combined with Protriptyline.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Protriptyline.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Protriptyline is combined with Entacapone.Approved, Investigational
EphedraProtriptyline may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Protriptyline can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Protriptyline.Approved, Investigational
EpinephrineProtriptyline may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ergonovine.Approved
ErgotamineProtriptyline may decrease the antihypertensive activities of Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Protriptyline.Approved, Investigational
ErythromycinProtriptyline may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Protriptyline.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Protriptyline.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Protriptyline.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Protriptyline.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Protriptyline.Approved
EthanolProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Protriptyline.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Protriptyline.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ethotoin.Approved
Ethyl biscoumacetateProtriptyline may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Protriptyline.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Protriptyline.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Protriptyline.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Protriptyline.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Protriptyline.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Protriptyline.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Protriptyline.Approved
EtomidateProtriptyline may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Etoperidone.Withdrawn
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Protriptyline.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Protriptyline.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Protriptyline.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Protriptyline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Protriptyline can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Protriptyline.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Protriptyline.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Protriptyline.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Protriptyline.Approved
FlecainideProtriptyline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Protriptyline.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Protriptyline.Approved, Illicit
FluindioneProtriptyline may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Protriptyline.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Protriptyline.Approved, Vet Approved
FlupentixolProtriptyline may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Protriptyline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Protriptyline.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Protriptyline.Approved, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Protriptyline.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Protriptyline.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Protriptyline can be increased when it is combined with Fosamprenavir.Approved
FosinoprilThe serum concentration of Protriptyline can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Protriptyline.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Frovatriptan.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Protriptyline.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Protriptyline.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Protriptyline is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Protriptyline can be increased when it is combined with Gabexate.Investigational
Gadobenic acidProtriptyline may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Protriptyline.Approved, Illicit, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Protriptyline.Approved, Investigational
GeldanamycinThe serum concentration of Protriptyline can be increased when it is combined with Geldanamycin.Experimental, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Protriptyline.Approved
GemifloxacinProtriptyline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineProtriptyline may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Protriptyline.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Protriptyline.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Protriptyline.Approved, Illicit
GM6001The serum concentration of Protriptyline can be increased when it is combined with GM6001.Experimental
GoserelinProtriptyline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronProtriptyline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Protriptyline.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Protriptyline.Investigational, Withdrawn
GuanabenzProtriptyline may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineProtriptyline may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Protriptyline.Approved, Illicit, Withdrawn
HaloperidolProtriptyline may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Protriptyline.Approved, Vet Approved
HarmalineHarmaline may increase the serotonergic activities of Protriptyline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Protriptyline.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Protriptyline can be increased when combined with Hexobarbital.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Protriptyline.Experimental
HydrocodoneProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Protriptyline.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Protriptyline.Approved, Illicit
HydroxyamphetamineProtriptyline may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Protriptyline.Approved
IbutilideProtriptyline may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Protriptyline.Approved
IdraparinuxThe serum concentration of Protriptyline can be increased when it is combined with Idraparinux.Investigational
IloperidoneProtriptyline may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Protriptyline.Approved
ImidaprilThe serum concentration of Protriptyline can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Imipramine.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Protriptyline.Approved
IndalpineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Protriptyline can be increased when it is combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Protriptyline.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Protriptyline.Approved, Investigational
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Protriptyline.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Protriptyline.Approved, Investigational
Iofetamine I-123Protriptyline may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideIproclozide may increase the serotonergic activities of Protriptyline.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Protriptyline.Withdrawn
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Protriptyline.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Protriptyline.Approved, Vet Approved
IsoflurophateThe serum concentration of Protriptyline can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Protriptyline can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Isoprenaline.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Protriptyline.Approved, Vet Approved
IxazomibThe serum concentration of Protriptyline can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Protriptyline.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Protriptyline.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Protriptyline.Approved, Investigational
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Protriptyline.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Protriptyline.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Protriptyline.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Protriptyline.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Protriptyline.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Protriptyline.Approved
LenvatinibProtriptyline may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinThe serum concentration of Protriptyline can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Protriptyline can be increased when it is combined with Letaxaban.Investigational
LeuprolideProtriptyline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Protriptyline.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Protriptyline.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levodopa.Approved
LevofloxacinProtriptyline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Protriptyline.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levomilnacipran.Approved
LevonordefrinProtriptyline may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Protriptyline.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Protriptyline.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Protriptyline.Approved, Vet Approved
LinagliptinThe serum concentration of Protriptyline can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Protriptyline.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Protriptyline.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Protriptyline.Approved
LisdexamfetamineProtriptyline may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Protriptyline can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Protriptyline.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Protriptyline.Illicit
LofexidineProtriptyline may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Protriptyline.Approved
LopinavirProtriptyline may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Protriptyline.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Protriptyline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Protriptyline.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Protriptyline.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Protriptyline.Approved
LumefantrineProtriptyline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Vet Approved
ManidipineThe metabolism of Protriptyline can be decreased when combined with Manidipine.Approved, Investigational
MannitolThe serum concentration of Mannitol can be increased when it is combined with Protriptyline.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.Approved
MebanazineMebanazine may increase the serotonergic activities of Protriptyline.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Protriptyline.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Protriptyline.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Protriptyline.Vet Approved
MelagatranThe serum concentration of Protriptyline can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Protriptyline.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Protriptyline.Approved, Investigational
MephedroneProtriptyline may increase the stimulatory activities of Mephedrone.Investigational
MephentermineProtriptyline may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Protriptyline.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Protriptyline.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Protriptyline.Approved, Investigational
MetaraminolProtriptyline may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Protriptyline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Protriptyline.Approved, Illicit
MethamphetamineProtriptyline may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Protriptyline.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Protriptyline.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Protriptyline can be increased when combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Protriptyline.Approved
MethotrimeprazineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineProtriptyline may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Protriptyline.Approved, Investigational, Vet Approved
MethoxyphenamineProtriptyline may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Protriptyline.Experimental
Methylene blueProtriptyline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Protriptyline.Approved, Investigational
MethylphenobarbitalThe metabolism of Protriptyline can be increased when combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Protriptyline.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Protriptyline.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Protriptyline.Approved, Investigational
MetyrosineProtriptyline may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Protriptyline.Approved, Illicit
MidodrineProtriptyline may increase the vasopressor activities of Midodrine.Approved
MidomafetamineProtriptyline may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Protriptyline can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Protriptyline.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Protriptyline is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Protriptyline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Protriptyline.Approved
MirtazapineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Protriptyline.Approved, Investigational
MMDAProtriptyline may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moclobemide.Approved
MoexiprilThe serum concentration of Protriptyline can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Protriptyline.Approved
MoperoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Moperone.Experimental
MorphineThe serum concentration of Morphine can be increased when it is combined with Protriptyline.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Mosapramine.Experimental
MoxifloxacinProtriptyline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Protriptyline.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Protriptyline can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Protriptyline.Approved
NafamostatThe serum concentration of Protriptyline can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Protriptyline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Protriptyline.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Protriptyline.Approved, Vet Approved
NaphazolineProtriptyline may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Naratriptan.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.Approved
NevirapineThe metabolism of Protriptyline can be decreased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Protriptyline.Withdrawn
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Protriptyline.Approved
NicorandilProtriptyline may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Protriptyline.Approved
NilotinibProtriptyline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Protriptyline.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Protriptyline.Approved
NitroaspirinThe serum concentration of Protriptyline can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Protriptyline.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Protriptyline.Approved
NorepinephrineProtriptyline may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Norflurane is combined with Protriptyline.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Protriptyline.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Nortriptyline.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Protriptyline.Withdrawn
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Protriptyline.Investigational
OfloxacinProtriptyline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Protriptyline.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Protriptyline can be increased when it is combined with Omapatrilat.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Protriptyline.Approved
OndansetronProtriptyline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Protriptyline.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Orciprenaline.Approved
OrphenadrineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Protriptyline.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Protriptyline.Approved
OtamixabanThe serum concentration of Protriptyline can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxethazaine is combined with Protriptyline.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Protriptyline.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Protriptyline.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Protriptyline.Approved, Illicit, Investigational
OxymetazolineProtriptyline may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Protriptyline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Oxypertine.Experimental
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Protriptyline.Approved, Vet Approved
PaliperidoneProtriptyline may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Protriptyline.Approved, Investigational
PanobinostatThe serum concentration of Protriptyline can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylinePargyline may increase the serotonergic activities of Protriptyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Protriptyline.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Protriptyline.Approved
Peginterferon alfa-2bThe serum concentration of Protriptyline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Protriptyline.Experimental
PentamidineProtriptyline may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Protriptyline.Approved, Vet Approved
PentobarbitalThe metabolism of Protriptyline can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Protriptyline.Investigational
PerflutrenProtriptyline may increase the QTc-prolonging activities of Perflutren.Approved
PergolideProtriptyline may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Protriptyline can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Protriptyline.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Protriptyline.Approved
PethidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Protriptyline.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Protriptyline.Experimental
PhenindioneProtriptyline may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the serotonergic activities of Protriptyline.Withdrawn
PhenobarbitalThe metabolism of Protriptyline can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Protriptyline.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Protriptyline.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Protriptyline.Withdrawn
PhenprocoumonProtriptyline may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineProtriptyline may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineProtriptyline may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineProtriptyline may decrease the antihypertensive activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Protriptyline.Approved, Vet Approved
PhosphoramidonThe serum concentration of Protriptyline can be increased when it is combined with Phosphoramidon.Experimental
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Protriptyline.Approved
PimozideProtriptyline may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Protriptyline.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Protriptyline.Investigational
PirlindolePirlindole may increase the serotonergic activities of Protriptyline.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Protriptyline.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Protriptyline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Protriptyline.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Protriptyline.Approved
PramipexoleProtriptyline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Protriptyline.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Protriptyline.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Protriptyline.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Protriptyline.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Protriptyline.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Protriptyline.Approved
PrimaquineProtriptyline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Protriptyline can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Protriptyline can be increased when it is combined with Prinomastat.Investigational
ProcainamideProtriptyline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Protriptyline.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Protriptyline.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Protriptyline.Approved, Vet Approved
PromazineProtriptyline may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promethazine.Approved
PropafenoneProtriptyline may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Protriptyline.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Protriptyline.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Protriptyline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Protriptyline.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Protriptyline.Approved, Investigational
ProthipendylThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prothipendyl.Investigational
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Protriptyline.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Protriptyline.Investigational
PseudoephedrineProtriptyline may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Protriptyline.Approved, Illicit
QuetiapineProtriptyline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe serum concentration of Protriptyline can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineProtriptyline may increase the QTc-prolonging activities of Quinidine.Approved
QuinineProtriptyline may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Quinisocaine is combined with Protriptyline.Experimental
RacecadotrilThe serum concentration of Protriptyline can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Protriptyline.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Protriptyline can be increased when it is combined with Ramipril.Approved
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Protriptyline.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Protriptyline.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Protriptyline.Approved
RemikirenThe serum concentration of Protriptyline can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Protriptyline.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Protriptyline.Approved, Investigational
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Protriptyline.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Protriptyline.Approved, Investigational
RisperidoneProtriptyline may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ritanserin is combined with Protriptyline.Investigational
RitobegronProtriptyline may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Protriptyline can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Protriptyline can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Rizatriptan.Approved
RolapitantThe metabolism of Protriptyline can be decreased when combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Protriptyline.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Protriptyline.Vet Approved
RopiniroleProtriptyline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Protriptyline.Approved
RotigotineProtriptyline may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Protriptyline.Approved
S-3304The serum concentration of Protriptyline can be increased when it is combined with S-3304.Investigational
SafrazineSafrazine may increase the serotonergic activities of Protriptyline.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salbutamol.Approved, Vet Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Protriptyline.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Salmeterol.Approved
SaquinavirThe serum concentration of Protriptyline can be increased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Protriptyline can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Protriptyline can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Protriptyline.Approved
SepranoloneThe risk or severity of adverse effects can be increased when Sepranolone is combined with Protriptyline.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Protriptyline.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Protriptyline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Protriptyline.Approved
SimeprevirThe serum concentration of Protriptyline can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Protriptyline can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Protriptyline can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sodium phosphate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Protriptyline.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Protriptyline.Approved, Investigational
SotalolProtriptyline may increase the QTc-prolonging activities of Sotalol.Approved
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Protriptyline.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Protriptyline.Experimental
SpiraprilThe serum concentration of Protriptyline can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Protriptyline can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe metabolism of Protriptyline can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.Approved, Investigational
SulfisoxazoleProtriptyline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Protriptyline.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Protriptyline.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Protriptyline is combined with Sumatriptan.Approved, Investigational
SuvorexantProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Protriptyline.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Protriptyline.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Protriptyline.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Protriptyline.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Protriptyline.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Protriptyline.Approved
TelaprevirThe serum concentration of Protriptyline can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinProtriptyline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinProtriptyline may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Protriptyline.Approved
TemocaprilThe serum concentration of Protriptyline can be increased when it is combined with Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Protriptyline.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Terbutaline.Approved
TetrabenazineProtriptyline may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Protriptyline.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Protriptyline.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Protriptyline.Investigational
ThalidomideProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe metabolism of Protriptyline can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Protriptyline can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Thioproperazine.Approved
ThioridazineProtriptyline may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Protriptyline can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Protriptyline.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Protriptyline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Protriptyline.Approved, Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Protriptyline.Approved
TiclopidineThe metabolism of Protriptyline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Protriptyline.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Protriptyline.Experimental
TimololThe serum concentration of Timolol can be increased when it is combined with Protriptyline.Approved
TioclomarolProtriptyline may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Protriptyline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineProtriptyline may decrease the antihypertensive activities of Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Protriptyline.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Protriptyline.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Protriptyline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Protriptyline.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Protriptyline.Approved, Investigational
ToremifeneProtriptyline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolProtriptyline may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Protriptyline can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Protriptyline.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Protriptyline.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Protriptyline.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Protriptyline.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Protriptyline.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Protriptyline.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Protriptyline.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Protriptyline.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Protriptyline.Approved, Investigational
UbenimexThe serum concentration of Protriptyline can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Protriptyline can be increased when it is combined with Ulinastatin.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Protriptyline.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Protriptyline.Approved
Valproic AcidThe serum concentration of Protriptyline can be increased when it is combined with Valproic Acid.Approved, Investigational
VandetanibProtriptyline may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Protriptyline.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Protriptyline.Approved
VemurafenibProtriptyline may increase the QTc-prolonging activities of Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Protriptyline.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Protriptyline.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Protriptyline.Experimental
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Protriptyline.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vilazodone.Approved
VildagliptinThe serum concentration of Protriptyline can be increased when it is combined with Vildagliptin.Approved, Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Protriptyline.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Protriptyline.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Protriptyline.Experimental
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Protriptyline.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vortioxetine.Approved
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Protriptyline.Approved
WarfarinProtriptyline may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Xenon is combined with Protriptyline.Experimental
XimelagatranThe serum concentration of Protriptyline can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Protriptyline.Vet Approved
XylometazolineProtriptyline may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Protriptyline.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Protriptyline can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Protriptyline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Protriptyline.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zimelidine.Withdrawn
ZiprasidoneProtriptyline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZofenoprilThe serum concentration of Protriptyline can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Protriptyline.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Protriptyline.Approved, Investigational
ZolpidemProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Protriptyline is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Protriptyline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Protriptyline.Approved, Investigational
ZuclopenthixolProtriptyline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14488
KEGG Compound
C07408
PubChem Compound
4976
PubChem Substance
46505128
ChemSpider
4805
BindingDB
50176062
ChEBI
8597
ChEMBL
CHEMBL668
Therapeutic Targets Database
DAP000863
PharmGKB
PA451168
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Protriptyline
ATC Codes
N06AA11 — Protriptyline

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableCompletedTreatmentDepressive State1

Pharmacoeconomics

Manufacturers
  • Sanofi aventis us llc
  • Pfizer laboratories div pfizer inc
  • Roxane laboratories inc
  • Sigmapharm laboratories llc
  • Odyssey pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg/1
TabletOral5 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
Prices
Unit descriptionCostUnit
Tofranil-PM 30 125 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 150 mg capsule Bottle588.33USD bottle
Tofranil-PM 30 75 mg capsule Bottle588.33USD bottle
Tofranil 30 50 mg tablet Bottle185.09USD bottle
Tofranil-pm 100 mg capsule19.23USD capsule
Tofranil-pm 150 mg capsule18.86USD capsule
Tofranil-pm 75 mg capsule18.86USD capsule
Tofranil-pm 125 mg capsule18.68USD capsule
Anafranil 25 mg capsule13.51USD capsule
Anafranil 50 mg capsule13.51USD capsule
Anafranil 75 mg capsule13.24USD capsule
Tofranil 50 mg tablet6.64USD tablet
Norpramin 150 mg tablet6.23USD tablet
Surmontil 100 mg capsule5.92USD capsule
Tofranil 25 mg tablet4.97USD tablet
Tofranil 10 mg tablet4.73USD tablet
Norpramin 100 mg tablet4.27USD tablet
Surmontil 50 mg capsule4.15USD capsule
Vivactil 10 mg tablet4.05USD tablet
Norpramin 75 mg tablet3.27USD tablet
Protriptyline hcl 10 mg tablet3.07USD tablet
Vivactil 5 mg tablet2.86USD tablet
Norpramin 50 mg tablet2.59USD tablet
Surmontil 25 mg capsule2.49USD capsule
Protriptyline hcl 5 mg tablet2.12USD tablet
Norpramin 25 mg tablet1.4USD tablet
Norpramin 10 mg tablet1.16USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)169-171 °C (Protriptyline HCl)Not Available
water solubility1.04 mg/LNot Available
logP4.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000231 mg/mLALOGPS
logP4.65ALOGPS
logP4.5ChemAxon
logS-6.1ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity87.3 m3·mol-1ChemAxon
Polarizability31.6 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9862
Caco-2 permeable+0.7821
P-glycoprotein substrateSubstrate0.7406
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.5597
Renal organic cation transporterInhibitor0.6622
CYP450 2C9 substrateNon-substrate0.7206
CYP450 2D6 substrateSubstrate0.9034
CYP450 3A4 substrateSubstrate0.5285
CYP450 1A2 substrateNon-inhibitor0.7595
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.641
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7512
Ames testNon AMES toxic0.6
CarcinogenicityNon-carcinogens0.9322
BiodegradationNot ready biodegradable0.7732
Rat acute toxicity3.0087 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.736
hERG inhibition (predictor II)Inhibitor0.8132
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-006x-8910000000-ec599ee02d998905757e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organic tricyclic compound (CHEBI:8597)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  4. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ: [3H]nisoxetine--a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments. Neuropharmacology. 1996 Jan;35(1):63-70. [PubMed:8684598]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serotonin:sodium symporter activity
Specific Function
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into t...
Gene Name
SLC6A4
Uniprot ID
P31645
Uniprot Name
Sodium-dependent serotonin transporter
Molecular Weight
70324.165 Da
References
  1. McDougle CJ, Epperson CN, Price LH, Gelernter J: Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998 May;3(3):270-3. [PubMed:9672904]
  2. Rouillon F, Blachier C, Dreyfus JP, Bouhassira M, Allicar MP: [Pharmaco-epidemiologic study of the use of antidepressant drugs in the general population]. Encephale. 1996 May;22 Spec No 1:39-48. [PubMed:8767026]
  3. Frazer A, Daws LC: Serotonin transporter function in vivo: assessment by chronoamperometry. Ann N Y Acad Sci. 1998 Dec 15;861:217-29. [PubMed:9928259]
  4. Daws LC, Toney GM, Gerhardt GA, Frazer A: In vivo chronoamperometric measures of extracellular serotonin clearance in rat dorsal hippocampus: contribution of serotonin and norepinephrine transporters. J Pharmacol Exp Ther. 1998 Aug;286(2):967-76. [PubMed:9694957]
  5. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821]
  6. Kovachich GB, Aronson CE, Brunswick DJ: Effect of repeated administration of antidepressants on serotonin uptake sites in limbic and neocortical structures of rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 1992 Dec;7(4):317-24. [PubMed:1476595]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:36